Abstract: Disclosed herein are compounds, compositions and methods for the treatment of neurological, psychiatric disorders which are characterized by a fundamental disruption of social behaviour, and substance use disorders. In particular, disclosed herein are compounds of Formula (I), or salts or prodrugs thereof. Methods of treating or preventing neurological, psychiatric disorders and substance use disorders, using compounds of Formula (I), or salts and prodrugs are also disclosed.
Type:
Grant
Filed:
May 7, 2021
Date of Patent:
February 6, 2024
Assignee:
Kinoxis Therapeutics Pty Ltd
Inventors:
Iain Stewart McGregor, Michael Kassiou, Michael Thomas Bowen, Callum Hicks, William Jorgensen
Abstract: Disclosed herein are compounds according to Formula I; a pharmaceutical composition including, consisting essentially of, or consisting of: a pharmaceutically acceptable compound of Formula I and a pharmaceutically acceptable carrier, diluent, or excipient; the use of compounds of Formula I in the preparation of a medicament; and a method including administering a pharmaceutical compositions comprising the compound of Formula I to a patient. The compounds, compositions, use, and methods are directed to the treatment of neurological, psychiatric disorders which are characterised by a fundamental disruption of social behaviour, and substance use disorders.
Type:
Grant
Filed:
June 12, 2019
Date of Patent:
November 8, 2022
Assignee:
Kinoxis Therapeutics Pty Ltd
Inventors:
Michael Kassiou, William Jorgensen, Eryn Werry, Tristan Reekie, Michael Bowen, Iain McGregor
Abstract: The present disclosure relates to compounds of Formula I being cyclic metabolites of oxytocin. These derivatives have enhanced selectivity for the oxytocin receptor.
Type:
Grant
Filed:
September 27, 2018
Date of Patent:
August 16, 2022
Assignee:
Kinoxis Therapeutics Pty Ltd
Inventors:
Michael Kassiou, Damien Gulliver, Tristan Reekie, Timothy Katte, William Jorgensen, Eryn Werry
Abstract: Disclosed herein are compounds, compositions and methods for the treatment of neurological, psychiatric disorders which are characterised by a fundamental disruption of social behaviour, and substance use disorders. In particular, disclosed herein are compounds of Formula (I), or salts or prodrugs thereof. Methods of treating or preventing neurological, psychiatric disorders and substance use disorders, using compounds of Formula (I), or salts and prodrugs are also disclosed.
Type:
Grant
Filed:
July 6, 2016
Date of Patent:
June 15, 2021
Assignee:
Kinoxis Therapeutics Pty Ltd
Inventors:
Iain Stewart McGregor, Michael Kassiou, Michael Thomas Bowen, Callum Hicks, William Jorgensen